Zhejiang Xianju Pharmaceutical Co Ltd Asset Resilience Ratio
Zhejiang Xianju Pharmaceutical Co Ltd asset resilience ratio. Zhejiang Xianju Pharmaceutical Co Ltd (002332) has an Asset Resilience Ratio of 6.02% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zhejiang Xianju Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zhejiang Xianju Pharmaceutical Co Ltd (2015–2021)
Asset resilience ratio of Zhejiang Xianju Pharmaceutical Co Ltd from 2015 to 2021. This chart shows how Zhejiang Xianju Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Zhejiang Xianju Pharmaceutical Co Ltd (002332) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Xianju Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Zhejiang Xianju Pharmaceutical Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥404.51 Million | 6.02% |
| Total Liquid Assets | CN¥404.51 Million | 6.02% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Xianju Pharmaceutical Co Ltd maintains only 6.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Xianju Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Xianju Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Zhejiang Xianju Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2015–2021)
Zhejiang Xianju Pharmaceutical Co Ltd asset resilience ratio by year from 2015 to 2021. The table below shows the annual Asset Resilience Ratio data for Zhejiang Xianju Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 7.45% | CN¥500.64 Million ≈ $73.26 Million |
CN¥6.72 Billion ≈ $983.82 Million |
+0.13pp |
| 2020-12-31 | 7.32% | CN¥500.44 Million ≈ $73.23 Million |
CN¥6.84 Billion ≈ $1.00 Billion |
+4.37pp |
| 2017-12-31 | 2.95% | CN¥151.50 Million ≈ $22.17 Million |
CN¥5.13 Billion ≈ $751.35 Million |
-5.34pp |
| 2016-12-31 | 8.29% | CN¥300.00 Million ≈ $43.90 Million |
CN¥3.62 Billion ≈ $529.83 Million |
-1.89pp |
| 2015-12-31 | 10.18% | CN¥350.00 Million ≈ $51.22 Million |
CN¥3.44 Billion ≈ $503.23 Million |
-- |
About Zhejiang Xianju Pharmaceutical Co Ltd
Zhejiang Xianju Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid raw materials and preparations in China and internationally. The company offers gynecological, anesthesia, respiratory, dermatology, generic drug, and other products; active pharmaceutical ingredients (API), such as corticosteroids, sex hormone, progestero… Read more